000 01334 a2200361 4500
005 20250517031041.0
264 0 _c20160504
008 201605s 0 0 eng d
022 _a1756-591X
024 7 _a10.1039/c5mt00077g
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAtrián-Blasco, E
245 0 0 _aCopper(I) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand.
_h[electronic resource]
260 _bMetallomics : integrated biometal science
_cAug 2015
300 _a1229-32 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdamantane
_xanalogs & derivatives
650 0 4 _aAlzheimer Disease
_xdrug therapy
650 0 4 _aAmyloid beta-Peptides
_xchemistry
650 0 4 _aCopper
_xisolation & purification
650 0 4 _aHumans
650 0 4 _aOrganophosphorus Compounds
_xpharmacology
650 0 4 _aOxidation-Reduction
650 0 4 _aReactive Oxygen Species
_xmetabolism
700 1 _aCerrada, E
700 1 _aConte-Daban, A
700 1 _aTestemale, D
700 1 _aFaller, P
700 1 _aLaguna, M
700 1 _aHureau, C
773 0 _tMetallomics : integrated biometal science
_gvol. 7
_gno. 8
_gp. 1229-32
856 4 0 _uhttps://doi.org/10.1039/c5mt00077g
_zAvailable from publisher's website
999 _c24854715
_d24854715